3児の親さん薬剤師のブログ

とある薬剤師です。感染症治療を考える素材をちょこっと提供。noteもあります https://note.com/twin1980

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

BMJから報告された

PLACID トライアル

 

インドにおいて、464人の患者を対象としたランダム化比較第2相試験では、死亡率や中等度から重度の疾患進行に対する効果を示すことができませんでした。

 

症状3日以内のサブグループ解析でも差がつかなかったことは、

血漿の立場を弱めますね。

 

www.bmj.com

 

Abstract


Objective

To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.

 

Design

Open label, parallel arm, phase II, multicentre, randomised controlled trial.

 

Setting

39 public and private hospitals across India.

 

Participants

464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm).

 

Interventions

Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study.

 

Main outcome measure

Composite of progression to severe disease (PaO2/FiO2 <100 mm Hg) or all cause mortality at 28 days post-enrolment.

 

Results

Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54).

 

Conclusion

Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19.

 

Trial registration Clinical

Trial Registry of India CTRI/2020/04/024775.

 

 

 

レジデントのための感染症診療マニュアル 第4版

レジデントのための感染症診療マニュアル 第4版

  • 作者:青木 眞
  • 発売日: 2020/11/30
  • メディア: 単行本